caplacizumab


( Last Updated : May 9, 2022)
Generic Name:
caplacizumab
Project Status:
Pending
Therapeutic Area:
Acquired thrombotic thrombocytopenic purpura (aTTP)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cablivi
Project Line:
Reimbursement Review
Project Number:
SR0736-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Submission Type:
Resubmission
Fee Schedule:
Pending
Tumour Type:
N/A
Indications:
Cablivi (caplacizumab) is indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange (PE) and immunosuppressive therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.